Canadians Severely Underestimate Hepatitis B Risks, GSK Survey…

Event summary

GSK's survey of 1,061 Canadians shows 89% have little to no awareness of chronic hepatitis B (CHB).
Only 31% rank CHB as a high cancer risk, despite it causing 56% of liver cancer cases globally.
Just 14% report being tested for CHB, with 45% never considering testing due to perceived low risk.
55% incorrectly believe there is no treatment for CHB, and 75% are unaware vaccination can prevent it.

The big picture

GSK's survey highlights a critical gap in public health awareness, with chronic hepatitis B significantly underrecognized despite its role as the leading cause of liver cancer. The findings align with global WHO targets to eliminate viral hepatitis by 2030 and underscore the need for policy changes to improve screening and vaccination rates. This disconnect between perception and medical reality presents both a challenge and an opportunity for GSK in positioning its preventive and treatment solutions.

What we're watching

Public Health Strategy: Whether Canada will expand universal screening and infant vaccination programs following updated guidelines.
Awareness Campaigns: The effectiveness of GSK's efforts to educate Canadians on CHB risks and prevention through clinical dialogues.
Treatment Access: How broader eligibility criteria in updated guidelines will impact diagnosis and treatment rates for CHB.